Astellas Announces Acquisition of Quethera’s Ophthalmic Gene Therapy Program

 Astellas Announces Acquisition of Quethera’s Ophthalmic Gene Therapy Program

Astellas Announces Acquisition of Quethera’s Ophthalmic Gene Therapy Program

Shots:

  • The agreement involves Astellas to pay an upfront payment of £85Mn to Quethera’s shareholder’s 
  • Quethera uses recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells to treat glaucoma
  • In pre-clinical models, this gene therapy improved survival rates of retinal ganglion cells (RGCs) in pre-clinical models

Click here to read full press release/ article | Ref: Astellas | Image:  PRNewsWire

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post